Ranjana Mehta, MD
Pulmonary Disease · East Moriches, NYNPI 1407942147
Payments from drug & device makers
Across 228 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$839
- Novo Nordisk$472
- Boehringer Ingelheim$467
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$397
- Bayer$372
- Lilly USA, LLC$368
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,318100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 35 | $839 |
| Novo Nordisk | 22 | $472 |
| Boehringer Ingelheim | 24 | $467 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $397 |
| Bayer | 13 | $372 |
| Lilly USA, LLC | 18 | $368 |
| Regeneron Healthcare Solutions, Inc. | 3 | $366 |
| Pfizer | 14 | $260 |
| Amneal Pharmaceuticals LLC | 10 | $194 |
| THD America, Inc. | 1 | $183 |
| Merck | 8 | $149 |
| Daiichi Sankyo Inc. | 7 | $140 |
| GSK | 6 | $125 |
| Johnson & Johnson | 1 | $121 |
| Exact Sciences | 4 | $98 |
| AbbVie(2 entities) | 4 | $90 |
| Amgen | 4 | $78 |
| Phathom Pharmaceuticals, Inc. | 4 | $77 |
| Amarin Pharma, Inc. | 4 | $70 |
| Inspire Medical Systems, Inc. | 1 | $55 |
| Baxter Healthcare | 1 | $50 |
| Dynavax Technologies Corporation | 2 | $49 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| Abbott | 2 | $42 |
| Endo Pharmaceuticals Inc. | 2 | $34 |
| Novartis | 2 | $33 |
| Eisai Inc. | 1 | $24 |
| Ardelyx, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $18 |
| Shield Therapeutics Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Avvisto Therapeutics, LLC | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Philips North America LLC | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,330 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $178,087 |
| RybelsusSemaglutide | 53 | $96,927 |
| FarxigaDapagliflozin Propanediol | 51 | $69,786 |
| MounjaroTirzepatide | 30 | $59,687 |
| JardianceEmpagliflozin | 37 | $58,475 |
| EliquisApixaban | 41 | $53,563 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $28,758 |
| TrulicityDulaglutide | 14 | $27,819 |
| JanuviaSitagliptin Phosphate | 17 | $26,313 |
| XareltoRivaroxaban | 12 | $19,115 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $12,629 |
| CreonLipase/Protease/Amylase | 12 | $11,202 |
| Levothyroxine Sodium | 279 | $6,524 |
| Atorvastatin Calcium | 364 | $4,955 |
| SynthroidLevothyroxine Sodium | 57 | $4,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $472 | $275,014141 claims |
| Lilly USA, LLCMounjaro, Trulicity | $368 | $87,50644 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $467 | $71,10457 claims |
| AstraZenecaFarxiga | $839 | $69,78651 claims |
| PfizerEliquis | $260 | $53,56341 claims |
| GSKTrelegy Ellipta | $125 | $28,75837 claims |
| MerckJanuvia | $149 | $26,31317 claims |
| Johnson & JohnsonXarelto | $121 | $19,11512 claims |
| AbbVieCreon, Synthroid | $90 | $15,77269 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $194 | $7,792346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in East Moriches
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.